Judge says he’ll approve opioid settlement with OxyContin maker Purdue and Sackler family

NEW YORK (AP) – Lawyers representing OxyContin maker Purdue Pharma, branches of the Sackler family that own it, cities, states, counties, Native American tribes, people with addiction and others across the U.S. delivered a nearly unanimous message for a bankruptcy court judge Friday: Approve a plan to settle thousands of opioid-related lawsuits against the company.

If U.S. Bankruptcy Judge Sean Lane abides, it will close a long chapter – and maybe the entire book – on a legal odyssey over efforts to hold the company to account for its role in an opioid crisis connected to 900,000 deaths in the U.S. since 1999, including deaths from heroin and illicit fentanyl.

Friday’s closing arguments were wrapping up a three-day hearing over the bankruptcy plan for the company, which filed for protection six years ago as it faced lawsuits with claims that grew to trillions of dollars.

Marshall Huebner, a lawyer for Purdue, told the judge that he wishes he could “conjure up $40 trillion or $100 trillion to compensate those who have suffered unfathomable loss.” But without that possibility, he said: “The plan is entirely lawful, does the greatest good for the greatest number in the shortest available timeframe.”

The saga has been emotional and full of contentious arguments between the many groups that took Purdue to court, often exposing a possible mismatch between the quest for justice and the practical role of bankruptcy court.

The U.S. Supreme Court rejected a previous deal because it said it was improper for Sackler family members to receive immunity from lawsuits over opioids. In the new arrangement, entities who don’t opt into the settlement can sue them. Family members are collectively worth billions, but much of their assets are held in trusts in offshore accounts that would be hard to access through lawsuits.

This time, the government groups involved have reached an even fuller consensus and there’s been mostly subdued opposition from individuals. Out of more than 54,000 personal injury victims who voted on whether the plan should be accepted. just 218 said no. A larger number of people who are part of that group didn’t vote.

Unlike with other proceedings, there were no protests outside the courthouse.

A handful of objectors spoke Thursday at the hearing, sometimes interrupting the judge. Some said that only the victims, not the states and other government entities, should receive the funds in the settlement. Others wanted the judge to find the members of the Sackler family criminally liable – something Lane said is beyond the scope of the bankruptcy court, but that the settlement doesn’t bar prosecutors from pursuing.

A Florida woman whose husband struggled with addiction after being given OxyContin following an accident told the court that the deal isn’t enough.

“The natural laws of karma suggest the Sacklers and Purdue Pharma should pay for what they have done,” Pamela Bartz Halaschak said via video.

A flood of lawsuits filed by government entities against Purdue and other drugmakers, drug wholesalers and pharmacy chains began about a decade ago.

Most of the major ones have already settled for a total of about $50 billion, with most of the money going to fight the opioid crisis. There’s no mechanism for tracking where it all goes or overarching requirement to evaluate whether the spending is effective. Those hit the hardest generally haven’t had a say.

The Purdue deal would rank among the largest of them. Members of the Sackler family would be required to pay up to $7 billion and give up ownership of the company. None have been on its board or received payments since 2018. Unlike a similar hearing four years ago, none were called to testify in this week’s hearing.

The company would get a name change – to Knoa Pharma – and new overseers who would dedicate future profits to battling the opioid crisis. That could happen in the spring of 2026.

There are also some non-financial provisions. Certain members of the Sackler family would be required to give up involvement in companies that sell opioids in other countries.

Family members would also be barred from having their names added to institutions in exchange for charitable contributions. The name has already been removed from museums and universities.

And company documents, including many that would normally be subject to lawyer-client privilege, are to be made public.

Unlike the other major opioid settlements, individuals harmed by Purdue’s products would be in line for some money as part of the settlement. About $850 million would be set aside for them, with more than $100 million of that amount carved out to help children born dealing with opioid withdrawal.

About 139,000 people have active claims for the money. Many of them, however, have not shown proof that they were prescribed Purdue’s opioids and will receive nothing. Assuming about half of the individual claimants would qualify, lawyers expect that those who had prescriptions for at least six months would receive about $16,000 each and those who had them more briefly would get around $8,000, before legal fees that would reduce what people actually receive.

People will have until March 1 to agree not to sue the Sacklers and apply for the funds.

One woman who had a family member suffer from opioid addiction told the court by video Thursday that the settlement doesn’t help people with substance use disorder.

“Tell me how you guys can sleep at night knowing people are going to get so little money they can’t do anything with it,” asked Laureen Ferrante of Staten Island, New York.

Most of the money is to go to state and local governments to be used in their efforts to mitigate damage of the opioid epidemic. Overdose death numbers have been dropping in the past few years, a decline experts believe is partly due to the impact of settlement dollars.